Blue Zone Wealth Advisors LLC Buys 1,264 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Blue Zone Wealth Advisors LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,390 shares of the medical research company's stock after buying an additional 1,264 shares during the quarter. Thermo Fisher Scientific comprises 1.6% of Blue Zone Wealth Advisors LLC's portfolio, making the stock its 27th largest position. Blue Zone Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $5,668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Cypress Advisory Group LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $253,000. Intact Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after purchasing an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $1,121,000. W.H. Cornerstone Investments Inc. boosted its holdings in Thermo Fisher Scientific by 25.1% in the fourth quarter. W.H. Cornerstone Investments Inc. now owns 2,870 shares of the medical research company's stock worth $1,493,000 after acquiring an additional 576 shares in the last quarter. Finally, Van ECK Associates Corp raised its position in shares of Thermo Fisher Scientific by 19.7% in the 4th quarter. Van ECK Associates Corp now owns 418,365 shares of the medical research company's stock worth $217,646,000 after purchasing an additional 68,927 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO stock traded up $6.67 during midday trading on Monday, hitting $408.57. The company's stock had a trading volume of 2,163,939 shares, compared to its average volume of 1,911,959. The firm has a market capitalization of $154.23 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The company has a 50 day moving average of $419.12 and a two-hundred day moving average of $494.94.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.11 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TMO. Argus reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Finally, UBS Group reduced their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $605.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.